Citizens JMP analyst Reni Benjamin initiated coverage of Compass Therapeutics (CMPX) with an Outperform rating and $10 price target The firm says the company’s most-advanced candidate, tovecimig, recently demonstrated a 17% overall response rate in combination with paclitaxel as a treatment for biliary tract cancers versus 5% for the paclitaxel comparison arm in a pivotal Phase 2/3 study. The analyst also believes CTX-10726 “could be a diamond in the rough” for Compass.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics’ CTX-10726: A Promising Leader in the Competitive PD-1 and VEGF Markets
- Compass Therapeutics Reports Q3 2025 Financial Results
- Positive Outlook for Compass Therapeutics: Buy Rating Justified by Promising Developments and Strong Financial Position
- Compass Therapeutics reports Q3 EPS (8c), consensus (13c)
- Compass Therapeutics presents preclinical data on CTX-10726